Vinyl Chloride Price Charts Now Available at Intratec Website

VCM historical prices and forecasts in several countries are now accessible through online charts.

SAN ANTONIO, TX, UNITED STATES, September 18, 2019 /EINPresswire.com/ — Intratec Solutions LLC, a leading provider of independent reports examining production processes and critical data surrounding industry-related markets, is pleased to announce that its online database now covers vinyl chloride price histories and forecasts.

Accessing online charts updated monthly, professionals interested in VCM pricing data can gain a solid understanding of price trends, in different global regions. The database covers vinyl chloride price histories and forecasts in the USA, Europe, and Asia, from 2007 to the present.

A free sample is available at www.intratec.us/chemical-markets/vinyl-chloride-price

Intratec offers very cost-effective subscription plans, designed for not only professionals needing continuous access to VCM pricing data but also users with a sporadic need to access such information. Subscribers may export pricing data into Excel format.

Intratec also offers professional and up-to-date reports focused on vinyl chloride production costs, detailing capital investment and operating costs of VCM plants. For more information, visit: www.intratec.us/analysis/vinyl-chloride-production-cost

About Intratec Solutions LLC

Intratec (www.intratec.us) is a leading provider of market and technology intelligence for process industries. Our business is about providing up-to-date and independent analyses examining production processes, as well as critical data surrounding industry-related markets. Our portfolio covers +900 products, among reports and online databases, which provide key information related to process industries, spanning: petrochemicals; plastics, rubbers & fibers; inorganic chemicals; fertilizers; renewable chemicals; specialty chemicals and energy & utilities.

PR Team
Intratec Solutions LLC
7139844834
email us here


Source: EIN Presswire

Breast Imaging Technologies Market 2019 Global Analysis, Growth, Size, Share, Trends, Forecast to 2025

PUNE, MAHARASHTRA, INDIA, September 18, 2019 /EINPresswire.com/ — Global Breast Imaging Technologies Market 2019-2025

New Study Reports Wiseguyreports.Com adds “Breast Imaging Technologies Market 2019 Global Industry Sales, Supply, Consumption, Demand, Analysis and Forecasts to 2025” To Its Research Database.

Report Summary:

The recent report found on WGR, on the global Breast Imaging Technologies market has provided insights on several factors that are posing as drivers for the Breast Imaging Technologies market over the assessment period. The report also includes different volume trends, value aspects of the product/service, and the pricing history of the same. Some primary factors driving substantial growth in the global Breast Imaging Technologies market include mounting global population, technological developments, different relevant government regulations introduced and their impact, and the demand and supply mechanism functioning in the Breast Imaging Technologies market.

This market is expected to witness significant growth during the forecast period owing to increase in incidence of breast cancer worldwide and proactive initiatives by healthcare organizations to raise awareness about early breast cancer detection. Moreover, improved reimbursement scenario for breast imaging modalities (such as breast ultrasound and 3D tomosynthesis which helps in the detection of breast cancer in women with dense breast tissue). In addition, launch of technological advanced modalities such as automated whole breast ultrasound system (AWBU) and MBI/BSGI) fuel the market growth. However, high cost of these modalities and stringent regulatory approval processes are expected to impede the breast imaging technologies market industry growth.

Drivers and Constraints

The fundamental dynamics that are explored in the report hold substantial influence over the Breast Imaging Technologies market. The report further studies on the value, volume trends, and the pricing history of the market. In addition to it, various growth factors, restraints, and opportunities are also analyzed for the market to study the in-depth understanding of the market.

It covers the sales volume, price, revenue, gross margin, manufacturers, suppliers, distributors, intermediaries, customers, historical growth and future perspectives in the Breast Imaging Technologies market.

The Leading Manufacturers covered in this study:
Dilon Technologies
FUJIFILM Holdings Corporation
Gamma Medica
General Electric Company
Hologic
Koning Corporation
Koninklijke Philips
Siemens AG
Sonociné
Toshiba Corporation
Aurora Imaging Technology
Carestream Health
Delphinus Medical Technologies
Micrima Limited
Tualatin Imaging

Request a Free Sample Report @ https://www.wiseguyreports.com/sample-request/4434483-global-breast-imaging-technologies-market-professional-survey-report-2019

Market divided by Type: 
Ionizing Breast Imaging Technologies
Non-Ionizing Breast Imaging Technologies

Market divided by Application: 
Hospitals
Clinics
Others

Market segment by Region/Country including: 

The analysis of the Breast Imaging Technologies market is also studied based on regions across the global level as well as regional level. Regionally, the report covers the key regions such as North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa. Each region is studied more profoundly, along with the latest trends, outlook, and promising opportunities in the Breast Imaging Technologies market share during the review period of 2025.

Key Stakeholders 
Breast Imaging Technologies Manufacturers 
Breast Imaging Technologies Distributors/Traders/Wholesalers 
Breast Imaging Technologies Subcomponent Manufacturers 
Industry Association 
Downstream Vendors

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@  https://www.wiseguyreports.com/reports/4434483-global-breast-imaging-technologies-market-professional-survey-report-2019

The report offers detailed insights regarding the global Breast Imaging Technologies market and the current trends; opportunities and threats related to the target market are also studied in the report.

The healthcare sector continues to grow at a rapid pace. Rising number of patients worldwide is putting more pressure on the sector. The doctor to population ration remains poor in third world countries and is viewed as a major challenge. However, efforts have increased towards delivering better care. Emphasis is being placed on improving both preventive and curative models. Such factors are adding new dimensions to the sector and thereby making more dynamic.

The global economy has been growing at a steady pace in recent years, which has reflected favorably on the per capita healthcare expenditure. At the same time, growing global population is driving the demand for healthcare services. This is prompting healthcare companies to deliver cost-effective services. Stricter healthcare regulations along with integration of digital platforms is making a positive impact on the overall quality of healthcare.

Some Points from Table of Contents:

8 Breast Imaging Technologies Major Manufacturers Analysis
8.1 Dilon Technologies
8.1.1 Dilon Technologies Breast Imaging Technologies Production Sites and Area Served
8.1.2 Dilon Technologies Product Introduction, Application and Specification
8.1.3 Dilon Technologies Breast Imaging Technologies Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 FUJIFILM Holdings Corporation
8.2.1 FUJIFILM Holdings Corporation Breast Imaging Technologies Production Sites and Area Served
8.2.2 FUJIFILM Holdings Corporation Product Introduction, Application and Specification
8.2.3 FUJIFILM Holdings Corporation Breast Imaging Technologies Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served

Continued…..

NORAH TRENT
Wise Guy Reports
841-198-5042
email us here
["facebook", "twitter", "linkedin"]
{"facebook"=>"", "twitter"=>"", "linkedin"=>""}


Source: EIN Presswire

FDA Ban: Brightens Path for Vaginal Mesh Lawsuit in Tennessee

FDA Restricted

Boston Scientific Corporation has been hit with a lawsuit filed by a woman who sustained injuries caused by the Uphold transvaginal mesh (TVM) device

The TVM devices on the market today.. are all unreasonably dangerous devices. Shamefully, they continue to be implanted in women without appropriate warning of the magnitude of risk…”

— Dr. Greg Vigna

SANTA BARBARA, CA, UNITED STATES, September 18, 2019 /EINPresswire.com/ — Boston Scientific Corporation has been hit with a lawsuit filed by a woman who sustained injuries caused by the Uphold transvaginal mesh (TVM) device used for the treatment of pelvic organ prolapse (POP) and the Obtryx transobturator sling used in the treatment of stress urinary incontinence (SUI). American Medical Systems, Inc. was also named in the lawsuit filed in United States District Court for the Middle District of Tennessee (Case No.: 3:19-cv-00820)

On April 16, 2019, the FDA ordered Boston Scientific Corporation and Coloplast ‘to stop selling and distributing their products (TVM devices for prolapse) immediately’ as there was no ‘demonstrated reasonable assurance of safety’ and their proposed prospective controlled 522 post-market surveillance study was deemed to be futile by FDA experts to show the necessary evidence that the benefit of the device out-weights the potential risks of the device. The Uphold device was, in effect, banned by the FDA.

Boston Scientific Corporation and Endo International PLC in the Tennessee complaint is accused of negligence for selling a defective medical device and failing to warn about safety risks and fraudulent concealment. American Medical Systems, Inc. was acquired by Endo International PLC in 2011 and renamed Astora Women’s Health. Endo closed Astora on March 31, 2016 after being named in over 46,000 TVM cases related to injuries caused by its polypropylene devices that include the Monarc sling, SPARC sling, and the Apogee, Perigee, and Elevate which were used for POP.

The Plaintiff and her husband are represented by Ben C. Martin and Laura Baughman of Martin Baughman, PLLC and Greg Vigna, MD, JD. Ben Martin and Laura Baughman are national pharmaceutical injury attorneys in Dallas, Texas. Dr. Vigna is a California and Washington DC lawyer who focuses on catastrophic injuries and the neurological injuries caused by transvaginal mesh devices including pudendal neuralgia, obturator neuralgia, and complex regional pain syndrome.

Dr. Vigna states, “We are filing severely injured women suffering with disabling injuries nationwide, associating with local attorneys. We have women that were implanted over a decade ago with TVM products that have recently become symptomatic as the device degrades and contracts pulling vital structures required for sexual, bowel, and bladder function. We also have women with severe neurological injuries causing catastrophic life change pain from 2019 implants.”

Dr. Vigna adds, “The TVM devices on the market today, like the ones banned by the FDA or the list of devices ‘voluntarily’ withdrawn from the marketplace, are all unreasonably dangerous devices. Shamefully, they continue to be implanted in women without appropriate warning of the magnitude of risk, leading to destroyed lives.”

For articles, video resources, and information visit the Pudendal Neuralgia Educational Portal or our website. To read our latest eBook with information regarding sling related complications, click here.

Greg Vigna
Greg Vigna, M.D., J.D.
1-800-761-9206
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Drug, Anti-infective Market 2019 analysis by Trends, Demand, Products and Suppliers Forecast to 2025

Drug, Anti-infective Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025

PUNE, MAHARASHTRA, INDIA, September 18, 2019 /EINPresswire.com/ — Global Drug, Anti-infective Market 2019-2025

New Study Reports Wiseguyreports.Com adds “Drug, Anti-infective Market 2019 Global Industry Sales, Supply, Consumption, Demand, Analysis and Forecasts to 2025” To Its Research Database.

Report Summary:

The recent report found on WGR, on the global Drug, Anti-infective market has provided insights on several factors that are posing as drivers for the Drug, Anti-infective market over the assessment period. The report also includes different volume trends, value aspects of the product/service, and the pricing history of the same. Some primary factors driving substantial growth in the global Drug, Anti-infective market include mounting global population, technological developments, different relevant government regulations introduced and their impact, and the demand and supply mechanism functioning in the Drug, Anti-infective market.

Drivers and Constraints

The fundamental dynamics that are explored in the report hold substantial influence over the Drug, Anti-infective market. The report further studies on the value, volume trends, and the pricing history of the market. In addition to it, various growth factors, restraints, and opportunities are also analyzed for the market to study the in-depth understanding of the market.

It covers the sales volume, price, revenue, gross margin, manufacturers, suppliers, distributors, intermediaries, customers, historical growth and future perspectives in the Drug, Anti-infective market.

The Leading Manufacturers covered in this study:
Merck
Pfizer
Novartis AG
Gilead Sciences
Abbott
Wyeth
Sanofi-Aventis
Bristol-Myers Squibb
Johnson
Roche Pharma AG
Nanosphere
NanoViricides
Novabay Pharmaceuticals
Obetech
Optimer Pharmaceuticals
Basilea Pharmaceutica AG
Daiichi Sankyo
MerLion Pharma

Request a Free Sample Report @ https://www.wiseguyreports.com/sample-request/4438999-global-drug-anti-infective-market-professional-survey-report-2019

Market divided by Type: 
OTC
Rx Drugs

Market divided by Application: 
Hospital
Drugs Store
Other

Market segment by Region/Country including: 

The analysis of the Drug, Anti-infective market is also studied based on regions across the global level as well as regional level. Regionally, the report covers the key regions such as North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa. Each region is studied more profoundly, along with the latest trends, outlook, and promising opportunities in the Drug, Anti-infective market share during the review period of 2025.

Key Stakeholders 
Drug, Anti-infective Manufacturers 
Drug, Anti-infective Distributors/Traders/Wholesalers 
Drug, Anti-infective Subcomponent Manufacturers 
Industry Association 
Downstream Vendors

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@  https://www.wiseguyreports.com/reports/4438999-global-drug-anti-infective-market-professional-survey-report-2019

The report offers detailed insights regarding the global Drug, Anti-infective market and the current trends; opportunities and threats related to the target market are also studied in the report.

The healthcare sector continues to grow at a rapid pace. Rising number of patients worldwide is putting more pressure on the sector. The doctor to population ration remains poor in third world countries and is viewed as a major challenge. However, efforts have increased towards delivering better care. Emphasis is being placed on improving both preventive and curative models. Such factors are adding new dimensions to the sector and thereby making more dynamic.

The global economy has been growing at a steady pace in recent years, which has reflected favorably on the per capita healthcare expenditure. At the same time, growing global population is driving the demand for healthcare services. This is prompting healthcare companies to deliver cost-effective services. Stricter healthcare regulations along with integration of digital platforms is making a positive impact on the overall quality of healthcare.

Continued….

NORAH TRENT
Wise Guy Reports
841-198-5042
email us here
["facebook", "twitter", "linkedin"]
{"facebook"=>"", "twitter"=>"", "linkedin"=>""}


Source: EIN Presswire

Megestrol Market 2019 Global Analysis, Growth, Size, Share, Trends, Forecast to 2024

Wiseguyreports.Com Adds “Megestrol -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database

PUNE, MAHARASHTRA, INDIA, September 18, 2019 /EINPresswire.com/ — Megestrol Industry

Description

Megestrol is a medicine that is used to treat breast cancer and endometrial cancer. It is sometimes used to treat other kinds of cancer.

This report focuses on Megestrol volume and value at global level, regional level and company level. From a global perspective, this report represents overall Megestrol market size by analyzing historical data and future prospect. 
Regionally, this report categorizes the production, apparent consumption, export and import of Megestrol in North America, Europe, China, Japan, Southeast Asia and India. 

For each manufacturer covered, this report analyzes their Megestrol manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered: 

Pfizer 
Sandoz 
GSK 
Mayne Pharma 
Novartis 
Mylan 
Bristol Myers Squibb 
Abnova 
Abbott 
Takeda 
Guccess

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/4420316-global-megestrol-market-professional-survey-report-2019

Segment by Type 
Injection 
Freeze-Dried Powder

Segment by Application 
Hospital 
Clinic 
Others

Segment by Regions 
North America 
Europe 
China 
Japan 
Southeast Asia 
India

Leave a Query @ https://www.wiseguyreports.com/enquiry/4420316-global-megestrol-market-professional-survey-report-2019

Table of Contents

Executive Summary 
1 Industry Overview of Megestrol 
1.1 Definition of Megestrol 
1.2 Megestrol Segment by Type 
1.2.1 Global Megestrol Production Growth Rate Comparison by Types (2014-2025) 
1.2.2 Injection 
1.2.3 Freeze-Dried Powder 
1.3 Megestrol Segment by Applications 
1.3.1 Global Megestrol Consumption Comparison by Applications (2014-2025) 
1.3.2 Hospital 
1.3.3 Clinic 
1.3.4 Others 
1.4 Global Megestrol Overall Market 
1.4.1 Global Megestrol Revenue (2014-2025) 
1.4.2 Global Megestrol Production (2014-2025) 
1.4.3 North America Megestrol Status and Prospect (2014-2025) 
1.4.4 Europe Megestrol Status and Prospect (2014-2025) 
1.4.5 China Megestrol Status and Prospect (2014-2025) 
1.4.6 Japan Megestrol Status and Prospect (2014-2025) 
1.4.7 Southeast Asia Megestrol Status and Prospect (2014-2025) 
1.4.8 India Megestrol Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis 
2.1 Raw Material and Suppliers 
2.2 Manufacturing Cost Structure Analysis of Megestrol 
2.3 Manufacturing Process Analysis of Megestrol 
2.4 Industry Chain Structure of Megestrol

…..

8 Megestrol Major Manufacturers Analysis 
8.1 Pfizer 
8.1.1 Pfizer Megestrol Production Sites and Area Served 
8.1.2 Pfizer Product Introduction, Application and Specification 
8.1.3 Pfizer Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.1.4 Main Business and Markets Served 
8.2 Sandoz 
8.2.1 Sandoz Megestrol Production Sites and Area Served 
8.2.2 Sandoz Product Introduction, Application and Specification 
8.2.3 Sandoz Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.2.4 Main Business and Markets Served 
8.3 GSK 
8.3.1 GSK Megestrol Production Sites and Area Served 
8.3.2 GSK Product Introduction, Application and Specification 
8.3.3 GSK Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.3.4 Main Business and Markets Served 
8.4 Mayne Pharma 
8.4.1 Mayne Pharma Megestrol Production Sites and Area Served 
8.4.2 Mayne Pharma Product Introduction, Application and Specification 
8.4.3 Mayne Pharma Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.4.4 Main Business and Markets Served 
8.5 Novartis 
8.5.1 Novartis Megestrol Production Sites and Area Served 
8.5.2 Novartis Product Introduction, Application and Specification 
8.5.3 Novartis Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.5.4 Main Business and Markets Served 
8.6 Mylan 
8.6.1 Mylan Megestrol Production Sites and Area Served 
8.6.2 Mylan Product Introduction, Application and Specification 
8.6.3 Mylan Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.6.4 Main Business and Markets Served 
8.7 Bristol Myers Squibb 
8.7.1 Bristol Myers Squibb Megestrol Production Sites and Area Served 
8.7.2 Bristol Myers Squibb Product Introduction, Application and Specification 
8.7.3 Bristol Myers Squibb Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.7.4 Main Business and Markets Served 
8.8 Abnova 
8.8.1 Abnova Megestrol Production Sites and Area Served 
8.8.2 Abnova Product Introduction, Application and Specification 
8.8.3 Abnova Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.8.4 Main Business and Markets Served 
8.9 Abbott 
8.9.1 Abbott Megestrol Production Sites and Area Served 
8.9.2 Abbott Product Introduction, Application and Specification 
8.9.3 Abbott Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.9.4 Main Business and Markets Served 
8.10 Takeda 
8.10.1 Takeda Megestrol Production Sites and Area Served 
8.10.2 Takeda Product Introduction, Application and Specification 
8.10.3 Takeda Megestrol Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 
8.10.4 Main Business and Markets Served 
8.11 Guccess

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=4420316

Continued…            

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
email us here
{"facebook"=>"", "twitter"=>"", "linkedin"=>""}
["facebook", "twitter", "linkedin"]


Source: EIN Presswire

Herbal Supplement Market 2019, Global Industry Analysis, Size, Share, Growth, Trends and Forecast – 2024

A New Market Study, titled “Herbal Supplement Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

PUNE, INDIA, September 18, 2019 /EINPresswire.com/ — Summary

A New Market Study, titled “Herbal Supplement Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

This report provides in depth study of “Herbal Supplement Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Herbal Supplement Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This market report offers a comprehensive analysis of the global Herbal Supplement market. This report focused on Interdental Cleaners market past and present growth globally. Global research on Global Interdental Cleaners Industry presents a market overview, product details, classification, market concentration, and maturity study. The market value and growth rate from 2019-2025 along with industry size estimates are explained.

The latest advancements in Herbal Supplement industry and changing market dynamics are key driving factors to depict tremendous growth. Also, the risk factors which will have a significant impact on the Global Herbal Supplement industry in the coming years are listed in this report. The revenue-generating Herbal Supplement types, applications, and key regions are evaluated. Top growing regions and Herbal Supplement industry presence cover Asia-Pacific, North America, Europe, Middle East, African countries and South America. This Herbal Supplement business study also analyzes the top countries in these regions with their market potential.

Herbal supplements and remedies, sometimes called botanicals, have many active constituents, which are natural way of providing support for overall health and well-being. Also they can have drug-like effects.
Echinacea is used to prevent cold. Ginkgo is used to improve memory. Flaxseed is used to lower cholesterol level. The list of herbal supplements and remedies goes on and on. Herbal supplements and remedies including health care products and finished herbal products which extracted from herbs.
Herbal supplements and remedies are sold in many different forms – dried leaves for teas, powdered, as capsules or tablets, or in solution.
Herbal supplements and remedies are mainly extracted from plants, which have many active constituents, and are natural way of providing support for overall health and well-being. Also they can have drug-like effects. In China, herbal has been used as medicine to cure people since thousands years ago and they are good at curing chronic disease in comparison with the western medicine. Especially in recent years, resistance to drugs, toxic and side effects and other weaknesses of western medicine are more and more obvious, however herbal can solve these problems very well.

Request a Free Sample Report @ https://www.wiseguyreports.com/sample-request/4406796-global-herbal-supplement-market-professional-survey-report-2019

The global Herbal Supplement market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Herbal Supplement volume and value at global level, regional level and company level. From a global perspective, this report represents overall Herbal Supplement market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Herbal Supplement in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Herbal Supplement manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
NBTY(US)
Tsumura(JP)
Weleda(CH)
DSM(NL)
Nature’s Sunshine Products(US)
Madaus(DE)
Nutraceutical(US)
Arkopharma(FR)
Schwabe(DE)
Ricola(CH)
Blackmores(AU)
Dabur(IN)
Herbal Africa(ZA)
Pharma Nord APS(DM)
SIDO MUNCUL(ID)
Nature’s Answer (US)
TwinLab(US)
Pharmavite(US)b
Arizona Natural(US)
Potter’s Herbals(UK)
Tongrentang(CN)
TASLY(CN)
Yunnan Baiyao(CN)
Sanjiu(CN)
Zhongxin(CN)
Haiyao(CN)
Taiji(CN)
Kunming Pharma(CN)
JZJT(CN)
Guangzhou Pharma(CN)

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Mono – Herb Type
Multi – Herb Type

Segment by Application
Pharmaceutical Industry
Health Care Industry
Others

At Any Query @ https://www.wiseguyreports.com/enquiry/4406796-global-herbal-supplement-market-professional-survey-report-2019

Major Key Points in Table of Content

Executive Summary 
1 Industry Overview of Herbal Supplement 

2 Manufacturing Cost Structure Analysis 

3 Development and Manufacturing Plants Analysis of Herbal Supplement 

4 Key Figures of Major Manufacturers 

5 Herbal Supplement Regional Market Analysis 

6 Herbal Supplement Segment Market Analysis (by Type) 

7 Herbal Supplement Segment Market Analysis (by Application) 

8 Herbal Supplement Major Manufacturers Analysis 

9 Development Trend of Analysis of Herbal Supplement Market 

10.1 Marketing Channel

11 Market Dynamics 

12 Conclusion 

13 Appendix 

Continued….

Report Summary:
In the first section, the Global Herbal Supplement Market report presents industry overview, definition, and scope. The second part briefs about the Global Herbal Supplement industry bifurcation by Type, Application and Geographical regions. The top industry players, revenue analysis, and sales margin are explained. The production and consumption scenario is specified.

The SWOT analysis by players, the growth rate for each type, application, and the region is covered. A 5-year forecast Global Herbal Supplement industry perspective will lead to profitable business plans and informed moves. Towards, the end data sources, research methodology, and findings are offered.

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); Ph: +44 208 133 9349 (UK)

NORAH TRENT
Wise Guy Reports
841-198-5042
email us here
["facebook", "twitter", "linkedin"]
{"facebook"=>"", "twitter"=>"", "linkedin"=>""}


Source: EIN Presswire

Anju Software Completes Merger with OmniComm Sytems

PHOENIX, ARIZONA, UNITED STATES, September 18, 2019 /EINPresswire.com/ — Anju Software Inc. has completed the acquisition of OmniComm Systems, Inc. (OTCQX: OMCM), a leading strategic software solutions provider to the life sciences industry. Under the terms of the agreement, OmniComm is now a wholly owned subsidiary of Anju, a provider of data, software and services to life science companies, contract research organizations and medical device manufacturers.  Anju is a privately owned,  Abry Partners portfolio company.

The merger of OmniComm and Anju positions the combined organization as a leader in the eClinical solutions market, with particular expertise in electronic data capture and eSource. Anju is able to immediately add CTMS, eTMF, data migration and integration tools and dynamic reporting, integrated with the existing solutions, to the OmniComm suite of eClinical solutions. As part of the merger, OmniComm’s solutions, including its flagship TrialMaster® and TrialOne® products, will continue to be developed and supported with enhanced features to provide a complete eClinical suite.

“I am glad that two years of discussions with OmniComm has culminated in the acquisition of OmniComm by Anju.  With the financial backing of Abry Partners and the new technology available at Anju, we can realize the potential that both companies have to become the leader in providing software, data and services to the life sciences community.  For Anju customers, the addition of OmniCom Solutions provide data flow from early stage of clinical trials through safety and commercial life of drugs and medical devises” said Kurien Jacob, Founder and Chairman of Anju Software.

“This merger positions Anju as the fastest-growing provider in the eClinical arena, and the complementary products of the two companies now form a truly comprehensive eClinical suite,” commented Marc Eigner, CEO of Anju.

Madison Park Group LLC served as Anju’s advisor, and Snell & Wilmer L.L.P. served as Anju’s legal counsel in the transaction.

About OmniComm Systems, Inc.

OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations and other clinical trial sponsors principally located in the United States, Europe and East Asia. OmniComm’s proprietary EDC and eClinical software applications – TrialMaster®, TrialOne®, eClinical Suite, Promasys®, IRTMaster, AutoEncoder and Acuity – allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data. OmniComm is headquartered in Fort Lauderdale, FL.

For more information about OmniComm, visit: www.omnicomm.com

About Anju Software, Inc.

Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs and commercial divisions, including integrated data intelligence. Anju has combined deep industry and software domain expertise to build a next generation platform for the life sciences sector that can scale to provide solutions that meet customers’ needs from “molecule to retirement.” Anju provides end-to-end software solutions that help customers manage mission-critical pharma processes and turn data into actionable insights. Anju solutions are used by large and small pharmaceutical companies, contract research organizations, full-service agencies and medical device companies. Anju is headquartered in Tempe, AZ.

For more information about Anju, visit: www.anjusoftware.com

About Abry Partners

Abry is one of the most experienced and successful sector-focused private equity investment firms in North America. Since its founding in 1989, the firm has completed over $82.0 billion of leveraged transactions and other private equity or preferred equity placements.  Currently, the firm manages over $5.0 billion of capital across its active funds.

For more information on Abry, please visit: www.abry.com

Marc Eigner
Anju Software
+1 267-551-2995
email us here


Source: EIN Presswire

5.21% CAGR | Clinical Trials Market | Strategic Analysis | 2019-2025 | OGAnalysis

% of registered recruiting clinical studies worldwide by location as of August 2018

% of registered recruiting clinical studies worldwide by location as of August 2018

Clinical Trials Market is rapidly emerging with 5.21% CAGR growth over the forecast period

SOUTHLAKE, TX, UNITED STATES, September 18, 2019 /EINPresswire.com/ — Global Clinical Trials Market is witnessing strong growth by targeting untapped market opportunities in the field of pharmaceutical research and development, with around $200 billion spending estimated for global pharmaceutical R&D.

The 2109-2025 Clinical Trials market outlook presented by OG Analysis outlines globalization of clinical trials, innovations in treatments such as personalized medicine, technological evolution, and rise in CROs conducting clinical trials as key factors impacting the market growth.

US NIH statistics represent that the total number of registered clinical studies worldwide is 320,000 up to August 2019.

Further, digitization in biomedical research is paving way for growth of global clinical trials market. Followed by advent of e-clinical trials and clinical trials management system and their wide adoption by pharmaceutical and biopharmaceutical companies, contract research organizations and medical device companies are strengthening their clinical trial activities and market value.

Request Sample @ https://www.oganalysis.com/sample/217791

However, constraints of stringent licensing agreements and FDA approvals, huge investments in clinical trial setups and increase in clinical trials' complexity are among the key factors negatively impacting the market growth.

Prevalence of carcinogenic diseases paves strong clinical trials market growth

Clinical trial companies are adopting advanced technologies to streamline development of precision medicine and to drive industry standards for the treatment of rising poll of cancer diseases. WHO estimates Cancer as the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.

Further, increasing demand for expanded access program is pushing research hospitals to perform clinical trials for treatment of cancer and other rare disease conditions.

Further, various oncology drugs are routinely administered to patients prior to its approval by the U.S. FDA and considered as a part of expanded access trial. In September 2019, Medality Medical LLC U.S announced that it has received Institutional Review Board (IRB) approval from the University of Texas Health Science Center at San Antonio to commence human trials.

Browse Clinical Trials Market Research Report @ https://www.oganalysis.com/industry-reports/217791/clinical-trials-market

Strong R&D funds, pipeline of clinical trials shape the market size across medical-driven countries

The clinical trials market continues to showcase potential market growth across Americas and EU countries with in increasing R&D and strong clinical trial supplies across the regions. Accordingly a total of $15,023 million funds by National Institutes for Health for global clinical research through 2020 are estimated.

The presence of cluster of medical technology companies commencing clinical trials with increasing probability of Phase III success for new drugs and recordable percentage of population enrolling in clinical trials paves strong regional market growth. A recent statistical study reveals up to 5.4% population enrolled in clinical trial in the United States followed by 4.3% across EU-5.

The ongoing attempts of globalizing clinical research by key players in emerging markets such as China, Eastern Europe, Turkey, Argentina and Brazil play a critical role in advancing clinical trials market. For instance, in September 2019, CASI Pharmaceuticals gets approval for clinical trial from the Chinese National Medical Product Administration (NMPA), (counterpart as U.S FDA) for a clinical trial application for investigation in relapsed B-cell acute lymphoblastic leukemia.

Request for Special Discount on Clinical Trials Market report @ https://www.oganalysis.com/discount/217791

Huge investments, pipeline of clinical trials and collaborative approaches strengthen key players’ market share

Top pharmaceutical companies are increasing the R&D intensity for rapid drug development along with clinical trials to deliver precision medicine and therapeutic drug for high risk diseases. For instance, funding statistics of global pharmaceutical companies estimate 9.9 billion U.S. dollars spending by Johnson & Johnson.

Pipeline of clinical trials targeting cardiovascular and cancer diseases is observed across key players, for example, in September 2019, Intact Vascular, Inc announced III clinical trial will be presented during the high impact clinical research session of the 31st Transcatheter Cardiovascular Therapeutics meeting (Cardiovascular Research Foundation).

Further, in 2019, Kura Oncology announced that the first patient has been dosed in a Phase 1 clinical trial focused on the development of precision medicines for the treatment of cancer.

Key players of Clinical Trials Market include Johnson & Johnson, Clinipace, Laboratory Corporation of America, Eli Lilly and Company, ICON PLC, Novo Nordisk AS, PAREXEL International Corporation, Pfizer Inc., Pharmaceutical Product Development LLC, IQVIA, F. Hoffmann-La Roche Ltd, Sanofi, Wuxi AppTec

Related Reports
Clinical Trial Imaging Market
• Clinical Trial Supplies Market (https://www.oganalysis.com/industry-reports/216166/clinical-trial-supplies-market)

OGAnalysis-Market Intelligence Platform
Global Oil and gas industry annual subscription from OG ANALYSIS provides access to 11 databases including Exploration, Production, Refinery, LNG, Oil and Chemicals Storage, Pipelines, Market Intelligence, CAPEX, Tankers, small LNG and Trade.

About OG Analysis:
OG Analysis has been a trusted research partner for 10+ years delivering most reliable analysis, information and innovative solutions. OG Analysis is one of the leading players in market research industry serving 980+ companies across multiple industry verticals. Our core client centric approach comprehends client requirements and provides actionable insights that enable users to take informed decisions.

Contact Us:
Anil Kumar
Phone: +91-7337 01 3757
Email: sales@oganalysis.com
Website: https://www.oganalysis.com
Follow Us on LinkedIn: https://www.linkedin.com/company/og-analysis/

Anil Kumar
OG Analysis
+91 73370 13757
email us here


Source: EIN Presswire

Probiotic Ingredients Market 2019 Industry Trends, Top players, Demand, Share, Segmentation and Forecast to 2025

Wiseguyreports.Com Publish New Market Research Report On -“Probiotic Ingredients Market 2019 Global Analysis, Size, Share, Trends and Growth, Forecast 2025”

PUNE, INDIA, September 18, 2019 /EINPresswire.com/ —

Probiotic Ingredients Market 2019

This report includes a detailed study of the market. It is the result of a comprehensive research carried out keeping in mind the different parameters and trends dominating the global Probiotic Ingredients market. Both primary and secondary research has been carried out to arrive at the desired outcome. The primary research included feedback, opinion, and suggestion provided by the people and organization residing in the key markets as identified the industry experts. The data acquired from the primary research have been studied and converted into useful information. This information backed by inputs gathered from secondary research sources form the base of the report. Information has been gathered keeping in view the anticipated gauge time frame 2019-2025. The report includes an estimated worth of the entire industry and the CAGR at which the industry is likely to grow. The report has been divided under heads like market segmentation, regional analysis, and key players. These heads offer the readers and businesses the opportunity to locate the exact information they are looking for.

Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/4418356-global-probiotic-ingredients-market-professional-survey-report-2019

Key Players
A glimpse of the competition prevailing in the global Probiotic Ingredients market can be arrived at through the report. This part of the study has used SWOT analysis tools to narrow down the strengths, weaknesses, opportunities, and threats of each market player.

The following Top Manufacturers are covered:
Biena
Ganeden
LALLEMAND
Nebraska Cultures
UAS Laboratories
BIO-CAT Microbials
Deerland Enzymes
PROBI
Probiotic America
Sabinsa Corporation
Thera-Plantes

Key Drivers
The drivers that has significant impact on the global Probiotic Ingredients market have been identified in this report. In broader terms, the drivers have been categorized under economic, political, geographical, social, cultural, and technological factors affecting the Probiotic Ingredients market growth. The drivers can be independent or interconnected. Additionally, the drivers can vary over time.

Regional Description
Region is a crucial part of any study. The regional presence of the Probiotic Ingredients market has been thoroughly studied in the research report. To present a detailed picture about the market, the report has segmented the market as per the North America, Latin America, Europe, Middle East & Africa, Asia Pacific, and the Rest of the World. The overall patterns in every one of the area gives exact data about the market of that locale and expected difficulties can be measured simultaneously.

Research Methodology
For primary research, a sample of 100 people from each regional market have been asked to fill up the questionnaire. The questionnaire has been prepared according to the Likert scale. Later, the questionnaire has been analyzed and evaluated using a Pareto chart. For auxiliary research, a few online storehouses have been utilized.

Complete Report Details @ https://www.wiseguyreports.com/reports/4418356-global-probiotic-ingredients-market-professional-survey-report-2019

Norah Trent
wiseguyreports
646 845 9349 / +44 208 133 9349
email us here
["facebook", "twitter", "linkedin"]
{"facebook"=>"", "twitter"=>"", "linkedin"=>""}


Source: EIN Presswire

Halal Pharmaceuticals Market 2019 Global Share, Size & Forecast to 2025

Wise.Guy12

Wise.Guy.

Wiseguyreports.Com Adds “Global Halal Pharmaceuticals Market Insights, Forecast to 2025" To Its Research Database

PUNE, MAHARASTRA, INDIA, September 18, 2019 /EINPresswire.com/ — Wiseguyreports.Com Adds “Global Halal Pharmaceuticals Market Insights, Forecast to 2025" To Its Research Database

Description:-

Halal pharmaceuticals are those medicines that stringently adhere to Shariah law. More specifically, halal pharmaceuticals refer to medicines that should not contain any parts of animals (dogs, pigs and ones particularly with pointed teeth), insects (bees), alcohol and other substances prohibited as 'haram' under the Shariah law.

Scope of the Report:

In the last several years, global market of Halal Pharmaceuticals developed rapidly, with an average growth rate of 22.98%. In the next few years, Halal Pharmaceuticals industry will maintain increasing at a high growth rate. Investors are still optimistic about this area; the future will still have more new investment enter the field.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3717054-global-halal-pharmaceuticals-market-insights-forecast-to-2025

Southeast Asia and NAME is the main production places, with a revenue market share nearly 62% and 18% in 2016. Southeast Asia and NAME also is the main consumption region with market share 58% and 26% in 2016. The revenue is about 205.79 M USD the consumption need is around 36.7 B USD in 2016 and there is a huge gap in there.

The classification of Halal Pharmaceuticals includes Tablets, Syrups, Capsules and Other. The proportion of Tablets in 2016 is about 46%, and the proportion is in increasing trend from 2012 to 2016.
The global Halal Pharmaceuticals market is valued at 240 million US$ in 2018 and will reach 620 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Halal Pharmaceuticals market based on company, product type, end user and key regions.

The key players covered in this study

CCM Pharmaceuticals
Pharmaniaga
Rosemont Pharmaceuticals
Simpor Pharma
Bosch Pharmaceuticals
NOOR VITAMINS

……

For Detailed Report @ https://www.wiseguyreports.com/reports/3717054-global-halal-pharmaceuticals-market-insights-forecast-to-2025

The study objectives of this report are:

To study and analyze the global Halal Pharmaceuticals market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

To understand the structure of Halal Pharmaceuticals market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Halal Pharmaceuticals companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of Halal Pharmaceuticals submarkets, with respect to key regions.

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Major Key Points in Table of Content:

Leave a Query @ https://www.wiseguyreports.com/enquiry/3717054-global-halal-pharmaceuticals-market-insights-forecast-to-2025

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
email us here
{"facebook"=>"", "twitter"=>"", "linkedin"=>""}
["facebook", "twitter", "linkedin"]


Source: EIN Presswire